Patents Assigned to Chugai Seiyaku Kabushiki
  • Method of producing heterogeneous protein
    Patent number: 9284374
    Abstract: The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses alanine aminotransferase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: March 15, 2016
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hisahiro Tabuchi, Tomoya Sugiyama
  • Anti-CLDN6 antibody
    Patent number: 9274119
    Abstract: The present invention relates to an antibody binding to Claudin6 (CLDN6) expressed on a cell membrane. The antibody of the present invention recognizes human CLDN6 present in a native form on cell membrane surface and exhibits cytotoxicity through ADCC and/or CDC activities against cancer cell lines highly expressing human CLDN6. Moreover, the antibody of the present invention has cell growth inhibitory effect through conjugation with toxin on cancer cell lines highly expressing human CLDN6. The human CLDN6 is overexpressed in tumor tissues (lung adenocarcinoma, gastric cancer, and ovarian cancer), although its expression is not observed in normal tissues. Thus, the anti-CLDN6 antibody is expected to highly accumulate in tumors highly expressing human CLDN6 and can serve as a very effective antitumor agent.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: March 1, 2016
    Assignees: THE UNIVERSITY OF TOKYO, CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Hiroyuki Aburatani, Shuichi Tsutsumi, Kunihiro Nishimura, Hirofumi Sakumoto, Shigeto Kawai
  • Method for cancer immunotherapy
    Patent number: 9273148
    Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: March 1, 2016
    Assignees: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., CHUGAI SEIYAKU KABUSHIKI KAISHA, SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Toshio Nishihara, Masashi Gotoh
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO ANEXELEKTO, AND USE THEREOF
    Publication number: 20160053019
    Abstract: The present inventors have succeeded in producing anti-AXL antibodies with specific functions. The present inventors also discovered that the antibodies have an angiogenesis-suppressive effect and an antitumor effect, and thereby completed the present invention. The anti-AXL antibodies of the present invention are useful as angiogenesis inhibitors and agents for inducing or inhibiting phosphorylation activity.
    Type: Application
    Filed: September 9, 2015
    Publication date: February 25, 2016
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Takehisa Kitazawa, Tsukasa Suzuki, Shigehisa Nagahashi, Hajime Miyamoto
  • Orally available viridiofungin derivative possessing anti-HCV activity
    Patent number: 9266853
    Abstract: An object of the present invention is to provide a compound that is useful as an orally available anti-HCV agent. The present invention relates to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. This compound has an anti-HCV activity and is useful as a medicine.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: February 23, 2016
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yasunori Kohchi, Kimitaka Nakama, Susumu Komiyama, Fumio Watanabe
  • Antigen-Binding Molecule for Promoting Disappearance of Antigen via Fc gamma RIIB
    Publication number: 20160046693
    Abstract: The present invention provides antigen-binding molecules containing (i) an antigen-binding domain whose antigen-binding activity varies depending on ion concentration conditions, (ii) an Fc?R-binding domain having Fc? RIIb-selective binding activity, and (iii) an FcRn-binding domain having FcRn-binding activity under an acidic pH range condition, and methods of decreasing plasma antigen concentration as compared to before administering the molecule, which include the step of administering the molecule.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 18, 2016
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Yuki Iwayanagi, Kenta Haraya, Hitoshi Katada, Shojiro Kadono, Futa Mimoto
  • Fc REGION VARIANT
    Publication number: 20160039912
    Abstract: A polypeptide containing an antibody Fc region variant which has an amino acid sequence in which an amino acid alteration at position 238 according to EU numbering is combined with other specific amino acid alteration(s), was found to have decreased binding activities to all activating Fc?Rs, in particular Fc?RIIa (R type), while maintaining its Fc?RIIb-binding activity, when compared to a polypeptide containing a native IgG Fc region.
    Type: Application
    Filed: April 2, 2014
    Publication date: February 11, 2016
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Futa Mimoto, Hitoshi Katada, Tomoyuki Igawa
  • Therapeutic agent for chronic arthritides diseases of childhood-related diseases
    Patent number: 9255145
    Abstract: A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, Still's disease and the like, comprising an interleukin-6 (IL-6) antagonist as an active ingredient.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: February 9, 2016
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kazuyuki Yoshizaki, Norihiro Nishimoto, Masahiro Iwamoto, Seiji Minota, Shumpei Yokota, Takako Miyamae
  • Derivative of hyaluronic acid modified with amino-carboxylic acid
    Patent number: 9243077
    Abstract: The present invention provides a hyaluronic acid derivative comprising disaccharide units of Formula (I), and a hyaluronic acid derivative/drug conjugate wherein one or more drugs are conjugated to the hyaluronic acid derivative.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: January 26, 2016
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tomoko Yasugi, Yoshihiro Tampo, Kenji Yasugi, Tai Hirakura, Tsuyoshi Shimoboji
  • Pharmaceutical compositions containing sc(Fv)2
    Patent number: 9241994
    Abstract: The present inventor discovered stabilizing agents/stabilizing conditions for suppressing isomerization reactions of sc(Fv)2. It was also discovered that the above-mentioned isomerization reactions can be suppressed through use of freeze-dried formulations. As disclosed herein, by applying the discovered stabilizing agents/stabilizing conditions or the freeze-dried formulation, the isomerization reaction of an sc(Fv)2-type molecule from the bivalent scFv type to the single chain diabody type, and/or the isomerization reaction from a single chain diabody type to a bivalent scFv type can be suppressed in both directions or one direction.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: January 26, 2016
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventor: Tomoyuki Igawa
  • SPIROIMIDAZOLONE DERIVATIVE
    Publication number: 20160016956
    Abstract: The present invention relates to a compound represented by the following formula (1): wherein W, X, Y, R1, R2, R33, R34, m and n are as defined in the claims, or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: September 17, 2015
    Publication date: January 21, 2016
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Toru Esaki, Yoshikazu NISHIMURA, Yoshiaki ISSHIKI, Naoki OKAMOTO, Yoshiyuki FURUTA, Akemi MIZUTANI, Masateru OHTA, Wayne Wen LAI, Tomoya KOTAKE
  • Method for recombinant production of a desired polypeptide using a mammalian cell co-expressing a taurine transporter polypeptide
    Patent number: 9238687
    Abstract: The present invention provides a method capable of producing a natural or recombinant protein at low cost. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses a taurine transporter and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide. Hamster taurine transporter, a DNA encoding the same, a recombinant vector and a transformed cell are also provided.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: January 19, 2016
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hisahiro Tabuchi, Tomoya Sugiyama, Saeko Tanaka, Satoshi Tainaka
  • Antibody constant region variant
    Patent number: 9228017
    Abstract: By altering amino acid sequence, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production. That is, homogeneity of antibodies can be maintained at a high level by introducing the alterations provided by the present invention into the antibody heavy chain constant regions. More specifically, decrease in homogeneity caused by —SS— bond linkage differences in the heavy chains of antibody molecules can be prevented. Furthermore, in a preferred embodiment of the present invention, pharmacokinetics of antibodies can be improved and decrease in homogeneity caused by deletion of the C terminus in the antibody constant region can be ameliorated.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: January 5, 2016
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Hirotake Shiraiwa
  • Process for the synthesis of vitamin D compounds and intermediates for the synthesis of the compounds
    Patent number: 9221753
    Abstract: An object of the present invention is to provide a process for synthesizing a vitamin D compound by simple procedures at lower costs. The present invention provides a process for preparing a vitamin D compound and an intermediate thereof, comprising the step of: (a) mixing a ketone or aldehyde, a Wittig reagent, and a base; or (b) mixing a ketone or aldehyde and a Wittig reagent, and then adding a base to the resulting mixture.
    Type: Grant
    Filed: February 3, 2005
    Date of Patent: December 29, 2015
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Hirotaka Kashiwagi, Yoshiyuki Ono
  • ANTI-DLL3 ANTIBODY
    Publication number: 20150368355
    Abstract: It is intended to disclose an antibody which binds to DLL3 protein. Preferably, the antibody of the present invention recognizes a region from amino acids 216 to 492 in human DLL3 having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the antibody of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the antibody of the present invention and a diagnostic drug for cancer comprising the antibody of the present invention.
    Type: Application
    Filed: September 4, 2015
    Publication date: December 24, 2015
    Applicants: THE UNIVERSITY OF TOKYO, CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kenji YOSHIDA, Hiroyuki ABURATANI, Shumpei ISHIKAWA
  • ANTIGEN-BINDING MOLECULE FOR ELIMINATING AGGREGATED ANTIGENS
    Publication number: 20150353630
    Abstract: The present inventors discovered that incorporating an Fc region and an antigen-binding domain whose antigen-binding activity varies depending on ion concentration into an antigen-binding molecule that binds to an aggregate-forming antigen produces an antigen-binding molecule that can preferentially clear protein aggregates in comparison to protein monomers from plasma. Use of antigen-binding molecules of the present invention allows various diseases stemming from target tissues to be treated target-tissue-specifically. Use of antigen-binding molecules of the present invention enables treatment of diseases caused by protein aggregates.
    Type: Application
    Filed: May 30, 2013
    Publication date: December 10, 2015
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Naoka Hironiwa, Eriko Ito
  • HETERODIMERIZED POLYPEPTIDE
    Publication number: 20150344570
    Abstract: The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or the second polypeptide by conventional technology.
    Type: Application
    Filed: December 26, 2013
    Publication date: December 3, 2015
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Futa Mimoto, Hitoshi Katada, Hirotake Shiraiwa
  • Method for production of polypeptide
    Patent number: 9181540
    Abstract: The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses cysteine sulfinic acid decarboxylase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide. Hamster cysteine sulfinic acid decarboxylase, a DNA encoding the same, a recombinant vector and a transformed cell are also provided.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: November 10, 2015
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hisahiro Tabuchi, Satoshi Tainaka, Tomoya Sugiyama
  • METHOD OF PRODUCING HETEROGENEOUS PROTEIN
    Publication number: 20150315624
    Abstract: The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses alanine aminotransferase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide.
    Type: Application
    Filed: July 16, 2015
    Publication date: November 5, 2015
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hisahiro Tabuchi, Tomoya Sugiyama
  • Syringe cap
    Patent number: D748778
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: February 2, 2016
    Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, TAISEI KAKO CO., LTD.
    Inventors: Rieko Shiozaki, Yuji Yamanaka, Taiji Horita, Ippei Matsumoto, Kensuke Taniguchi